Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement